A simple and reliable reverse-phase high-performance liquid chromatographic procedure for determination of paclitaxel (taxol) in human serum

被引:15
作者
Andreeva, M
Niedmann, PD
Binder, L
Armstrong, VW
Meden, H
Binder, M
Oellerich, M
机构
[1] MED UNIV SOFIA,DEPT CLIN LAB & CLIN IMMUNOL,SOFIA,BULGARIA
[2] UNIV GOTTINGEN,GEBURTSHILFE & GYNAKOL ABT,D-37075 GOTTINGEN,GERMANY
关键词
anticancer therapy; high-performance liquid chromatography; paclitaxel; taxol;
D O I
10.1097/00007691-199706000-00014
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A simple, fast, and reliable isocratic (mobile phase: acetonitrile/methanol/water [48/11/41]), reverse-phase (C18 column) high-performance liquid chromatography method for the determination of paclitaxel concentration in human serum is presented. The procedure uses a new and convenient one-step sample-purification procedure that requires only 400 mu l of sample and uses N-heptylbenzamide as an internal standard. Paclitaxel is detected by UV absorbance measurement at 227 nm. The method has a broad linear range (0.01 to 10 mg/l, or 0.012 to 11.7 mu mol/l; r > 0.999), and the detection limit is 0.01 mg/l (0.012 mu mol/l). The deviation from target value is less than or equal to 1.5%, and coefficients of variation are less than or equal to 13.8% within runs and less than or equal to 15.3% between runs. Recovery of paclitaxel is greater than or equal to 92.6%. No interferences were observed from endogenous compounds or from more than 30 drugs that may be administered with paclitaxel. Docetaxel, which is not concurrently administered, coeluted with paclitaxel. Compared with previously published high-performance liquid chromatography procedures for the determination of paclitaxel, the particular advantage of the method presented here is its simple and rapid single-step sample-purification procedure, which makes a high recovery of paclitaxel from serum samples possible and results in a pure extract, avoiding interferences from endogenous compounds. The method is suitable for pharmacological studies and routine analysis.
引用
收藏
页码:327 / 332
页数:6
相关论文
共 21 条
[1]  
ARBUCK SG, 1993, MONOGR NATL CANCER I, V15, P11
[2]  
BEIJNEN JH, 1994, SEMIN ONCOL, V21, P53
[3]   EXPEDIENT LIQUID-CHROMATOGRAPHIC ASSAY FOR PACLITAXEL IN PLASMA AFTER ITS ADMINISTRATION TO CANCER-PATIENTS [J].
ELYAZIGI, A ;
YUSUF, A .
THERAPEUTIC DRUG MONITORING, 1995, 17 (05) :511-515
[4]   TAXOL (PACLITAXEL) - A NOVEL ANTI-MICROTUBULE AGENT WITH REMARKABLE ANTINEOPLASTIC ACTIVITY [J].
FOA, R ;
NORTON, L ;
SEIDMAN, AD .
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1994, 24 (01) :6-14
[5]   NONLINEAR PHARMACOKINETICS AND METABOLISM OF PACLITAXEL AND ITS PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS IN HUMANS [J].
GIANNI, L ;
KEARNS, CM ;
GIANI, A ;
CAPRI, G ;
VIGANO, L ;
LOCATELLI, A ;
BONADONNA, G ;
EGORIN, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :180-190
[6]  
GREM JL, 1987, CANCER TREAT REP, V71, P1179
[7]  
HORWITZ SB, 1993, MONOGR NATL CANCER I, V15, P55
[8]   Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography [J].
Huizing, MT ;
Sparreboom, A ;
Rosing, H ;
vanTellingen, O ;
Pinedo, HM ;
Beijnen, JH .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 674 (02) :261-268
[9]   PHARMACOKINETICS OF PACLITAXEL AND METABOLITES IN A RANDOMIZED COMPARATIVE-STUDY IN PLATINUM-PRETREATED OVARIAN-CANCER PATIENTS [J].
HUIZING, MT ;
KEUNG, ACF ;
ROSING, H ;
VANDERKUIJ, V ;
HUININK, WWT ;
MANDJES, IM ;
DUBBELMAN, AC ;
PINEDO, HM ;
BEIJNEN, JH .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2127-2135
[10]   MECHANISM OF MITOTIC BLOCK AND INHIBITION OF CELL-PROLIFERATION BY TAXOL AT LOW CONCENTRATIONS [J].
JORDAN, MA ;
TOSO, RJ ;
THROWER, D ;
WILSON, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (20) :9552-9556